Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

Core Insights - Annovis Bio, Inc. is a Phase 3 clinical-stage biotechnology company focused on developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) [1][6] - The company announced two presentations at the 20th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2026), scheduled for March 17-21, 2026, in Copenhagen, Denmark [1][2] Presentation Highlights - The presentations will showcase clinical data supporting the treatment effect of buntanetap in PD, emphasizing cognition and biomarker findings, along with an update on the ongoing pivotal Phase 3 trial in early AD [2][4] - Cheng Fang, Ph.D., Senior VP of Research & Development, expressed pride in the progress of enrollment for the Alzheimer's disease pivotal study, indicating strong engagement from investigators and patients [4] Company Overview - Annovis Bio, headquartered in Malvern, Pennsylvania, is dedicated to developing treatments for neurodegenerative diseases, with its lead drug candidate, buntanetap, being an investigational once-daily oral therapy [6] - Buntanetap works by inhibiting the translation of multiple neurotoxic proteins through a specific RNA-targeting mechanism, aiming to halt disease progression and improve cognitive and motor functions in patients [6]